A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Clinical trial NCT04422912 · RECRUITING
Trial details
- NCT number
- NCT04422912
- Sponsor
- Cabaletta Bio
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-29
- Primary completion
- 2029-01-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.